Chronic Suppurative Otitis Media

Authored by Dr Laurence Knott, 04 Jan 2013

Reviewed by:
Dr Helen Huins, 04 Jan 2013

Patient professional reference

Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use. You may find the Glue Ear article more useful, or one of our other health articles.

Chronic suppurative otitis media (CSOM) is a chronic inflammation of the middle ear and mastoid cavity. Clinical features are recurrent otorrhoea through a tympanic perforation, with conductive hearing loss of varying severity. Experts dispute the duration of otorrhoea required to determine it as a chronic infection - the World Health Organization's definitions suggest more than two weeks; others contend longer (eg, up to six weeks).[1, 2]

The tympanic membrane is perforated in CSOM. If this is a tubotympanic perforation, it is usually 'safe', whilst atticoantral perforation is often 'unsafe'. Safe or unsafe depends on the presence of cholesteatoma:[3] 
  • Safe CSOM is CSOM without cholesteatoma. It can be subdivided into active or inactive depending on whether or not infection is present.
  • Unsafe CSOM involves cholesteatoma. Cholesteatoma is a non-malignant but destructive lesion of the skull base.

The underlying pathology of CSOM is an ongoing cycle of inflammation, ulceration, infection and granulation. Acute infection of the middle ear causes irritation and inflammation of the mucosa of the middle ear with oedema. Inflammation produces mucosal ulceration and breakdown of the epithelial lining. Granuloma formation can develop into polyps in the middle ear. This process may continue, destroying surrounding structures and leading to the various complications of CSOM.[4]

  • In Britain, 0.9% of children and 0.5% of adults have CSOM, with no difference between the sexes.
  • CSOM incidence rate is 4.76‰, equating to 31million cases, with 22.6% of cases occurring annually in the under-5s. 50% of CSOM patients suffer from hearing impairment.
  • Worldwide, there are between 65-330 million people affected, of whom 60% receive significant hearing loss. This burden falls disproportionately on children in developing countries.[5]

Risk factors[1, 4]

  • Multiple episodes of acute otitis media (AOM).
  • Living in crowded conditions.
  • Being a member of a large family.
  • Attending daycare.
  • Studies of parental education, passive smoking, breast-feeding, socio-economic status and the annual number of upper respiratory tract infections (URTIs) show inconclusive associations only.
  • Craniofacial anomalies increase risk: cleft lip or palate, Down's syndrome, cri du chat syndrome, choanal atresia and microcephaly all increase the risk of CSOM.

Otitis media (OM) is an umbrella term for a group of complex infective and inflammatory conditions affecting the middle ear. All OM involves pathology of the middle ear and middle ear mucosa. OM is a leading cause of healthcare visits worldwide and its complications are important causes of preventable hearing loss, particularly in the developing world.[5]

There are various subtypes of OM. These include AOM, otitis media with effusion (OME), chronic suppurative otitis media (CSOM), mastoiditis and cholesteatoma. They are generally described as discrete diseases  but in reality there is a great degree of overlap between the different types. OM can be seen as a continuum/spectrum of diseases:

  • AOM is acute inflammation of the middle ear and may be caused by bacteria or viruses. A subtype of AOM is acute suppurative OM, characterised by the presence of pus in the middle ear. In around 5% the eardrum perforates.
  • OME is a chronic inflammatory condition without acute inflammation, which often follows a slowly resolving AOM. There is an effusion of glue-like fluid behind an intact tympanic membrane in the absence of signs and symptoms of acute inflammation. 
  • CSOM is long-standing suppurative middle ear inflammation, usually with a persistently perforated tympanic membrane.
  • Mastoiditis is acute inflammation of the mastoid periosteum and air cells occurring when AOM infection spreads out from the middle ear.
  • Cholesteatoma occurs when keratinising squamous epithelium (skin) is present in the middle ear as a result of tympanic membrane retraction.


  • CSOM presents with a chronically draining ear (>2 weeks), with a possible history of recurrent AOM, traumatic perforation, or insertion of grommets.
  • The otorrhea should occur without otalgia or fever.
  • Fever, vertigo and otalgia should prompt urgent referral to exclude intratemporal or intracranial complications.
  • Hearing loss is common in the affected ear. Ask about the impact of this on speech development, school or work. Mixed hearing loss (conductive and sensorineural) suggests extensive disease.


  • The external auditory canal may possibly be oedematous but is not usually tender.
  • The discharge varies from fetid, purulent and cheese-like to clear and serous.
  • Granulation tissue is often seen in the medial canal or middle ear space.
  • The middle ear mucosa seen through the perforation may be oedematous or even polypoid, pale, or erythematous.
  • Otitis externa (inflamed, eczematous canal without a perforation).
  • Foreign body.
  • Impacted earwax.
  • Cholesteatoma.
  • Wegener's granulomatosis.
  • Neoplasm.

NB: chronic serous otitis media is not the same as chronic suppurative otitis media. The former may be defined as a middle ear effusion, without perforation, persisting for more than 1-3 months, depending on the author.

  • Do not swab the ear in primary care, as the clinical utility of this is uncertain.[2]
  • An audiogram will normally show conductive hearing loss.[7]One study found that the severity of hearing loss is associated with the size of the perforation.[5]Mixed hearing loss may suggest more extensive disease and possible complications.
  • Imaging studies may be useful:[4]
    • CT scanning for failed treatment may show occult cholesteatoma, foreign body or malignancy. It may be particularly helpful preoperatively.[8]
    • A fine-cut CT scan can reveal bone erosion from cholesteatoma, ossicular erosion, involvement of petrous apex and subperiosteal abscess.
    • MRI is better if intratemporal or intracranial complications are suspected. It shows soft tissues better and can reveal dural inflammation, sigmoid sinus thrombosis, labyrinthitis and extradural and intracranial abscesses.

Primary care

  • If there is postauricular swelling or tenderness (suggesting mastoiditis), facial paralysis, vertigo or evidence of intracranial infection, arrange urgent assessment or admission with an ENT team.
  • Refer cases of CSOM without these features for routine ENT assessment. Current Prodigy guidance suggests that GPs should not initiate treatment - this is because few non-specialists have the equipment or training to carry out aural cleaning; additionally, the topical antibiotics used by specialists are either used off-licence (quinolones) or are not recommended in the presence of tympanic perforation (aminoglycosides).[2]
  • Patients should be advised to keep the affected ear dry.
    Swimming advice:
    Patients with CSOM are usually advised to avoid swimming but, if they swim, they should dry their ears afterwards. Evidence is limited and there is consequently no consensus among specialists. Some advise ear plugs until grommets are extruded whilst others do not. Likewise, there is no agreement about whether diving should or should not be permitted whilst grommets are in situ.[9] 
  • Hearing tests are usual.

Secondary care

Conservative treatment of CSOM consists of three components:

  • An appropriate antibiotic, usually given topically.
  • Regular intensive aural toilet to remove debris.
  • Control of granulation tissue.


  • Aural toilet and topical antibiotics appear effective at resolving otorrhoea. Long-term outcomes (eg, healing of tympanic perforation, recurrence prevention and hearing improvement) need further study.
  • Topical treatment is more effective at clearing aural discharge than systemic therapy,[10]probably due to the higher local concentrations of antibiotic achieved.
  • Antibiotics should have activity against Gram-negative organisms, particularly pseudomonas and Gram-positive organisms, especially Staphylococcus aureus.
    • Aminoglycosides and the flouroquinolones both meet these criteria but there remain safety concerns with both. The Committee on Safety of Medicines (now the Commission on Human Medicines) advised that topical aminoglycosides should not be used with tympanic perforation, due to their ototoxicity.[11]However, many specialists continue to use them carefully, considering that undertreated otitis media carries a higher risk of hearing impairment and complications.
    • Topical quinolones are effective compared to no drug treatment or topical antiseptics only; however, evidence for their superiority over other topical antibiotics is only indirect.[12]UK specialists use either off-licence quinolones or aminoglycosides (because their effectiveness outweighs the risks of ototoxicity).[2]There are specific concerns about the use of flouroquinolones in children because of juvenile animal studies indicating a risk of joint injury in the young. Short-term treatment has been shown to be safe.[13]One study did find an association between ciprofloxacin and arthropathy in paediatric patients although the effect was reversible. No link was found between duration of administration and frequency of arthropathy.[13]
    • Antibiotic failure is usually due to failure to penetrate the debris rather than bacterial resistance.
  • Topical steroids are used to reduce granuloma formation and it is conventional to use combined antibiotic/steroid preparations.
  • Systemic therapy is reserved for failure to respond to topical therapy. If a focus of infection in the mastoid cannot be reached by topical drops, then systemically administered antibiotics (usually IV) can penetrate in sufficient concentrations to control or eliminate infection. Topical therapy is continued simultaneously. This is usually done in hospital with an accompanying regime of intensive aural toilet.
  • Treatment should continue for three to four weeks after the end of otorrhoea.


  • The type of surgery will depend on the severity of the disease process and may involve myringoplasty (repair of the eardrum perforation alone) or tympanoplasty (repair of the eardrum and surgery involving the bones of the inner ear).
  • If otoscopy reveals granulation tissue of the unsafe variety, aural polyps or infection persisting despite appropriate medical treatment, cholesteatoma should be sought. The goal of ensuing treatment is to create a safe ear, although the appropriate surgical procedure is often controversial.
  • If cholesteatoma is present (unsafe CSOM), classical radical mastoidectomy, modified radical mastoidectomy or the 'combined approach tympanoplasty' (anterior tympanotomy plus extended mastoidectomy) may be used depending on the extent of cholesteatoma and, more importantly, the experience of the surgeon. Whatever the procedure chosen, the aim of surgery is to remove all disease and to give the patient a dry and functioning ear.
  • Facial paralysis can occur with or without cholesteatoma. Surgical exploration with mastoidectomy should be undertaken promptly.
  • Labyrinthitis occurs when infection has spread to the inner ear. Early surgical exploration to remove the infection reduces damage to the labyrinth. Aggressive surgical debridement of the disease (including labyrinthectomy) is undertaken to prevent possibly fatal meningitis or encephalitis.
  • Where conductive hearing loss has resulted from CSOM (due to perforation of the tympanic membrane and/or disruption in the ossicular chain), surgical removal of the infection and cholesteatoma, followed by ossicular chain reconstruction, will reduce hearing loss.
  • Cochlear implants have been used in CSOM but it is essential to eradicate all disease first.[14]
  • The National Institute for Health and Clinical Excellence (NICE) recommends:[15]
    • Unilateral implant for all people who have severe or profound deafness which has not been improved by a three-month trial of a hearing aid.
    • Bilateral implants for severe or profoundly deaf children who have not benefited from a three-month trial of a hearing aid.
    • Bilateral implants for adults who have not benefited from a three-month trial of a hearing aid who have a disability such as blindness, which means they rely on hearing for spatial awareness.
Clinical Editor's Note (June 2017)
Dr Hayley Willacy notes that the Bone-anchored hearing aid system (BAHA) is a hearing aid which uses the principle of bone conduction. In individuals who are unable to hear using air conduction, either due to a congenital malformation of the ear canal or due to chronic ear infection, a hearing aid which utilises bone conduction is the most appropriate. There is evidence to support the use of bone anchored hearing devices in adults and children with hearing impairment that is not adequately corrected by conventional air conduction hearing aids[16] . The intervention is safe and of proven benefit.

Complications of CSOM are rare but potentially life-threatening.

Intratemporal complications include:

  • Petrositis
  • Facial paralysis[18]
  • Labyrinthitis

Intracranial complications include:

  • Lateral sinus thrombophlebitis
  • Meningitis
  • Intracranial abscess

Sequelae include:

Prognosis is good in developed countries where there is easy access to antibiotics and surgical treatment. However, in undeveloped countries the outcome can be variable. Otitis media caused 3,599 deaths worldwide in 2002, most cases due to spreading mastoid and intracranial infection.

Tympanic membrane perforations can heal spontaneously but can occasionally persist leading to mild to moderate hearing impairment. If this occurs in the first two years of life, it is associated with an increase in learning disabilities and a decrease in educational performance.

Further reading and references

  1. Acuin J; Chronic suppurative otitis media. Clin Evid (Online). 2007 Feb 12007. pii: 0507.

  2. Otitis media - chronic suppurative; Prodigy (October 2008)

  3. Aziz N et al, Inflammatory Diseases of the Middle Ear, Medscape, Sep 2012

  4. Parry D et al; Chronic Suppurative Otitis Media, Medscape, Oct 2011

  5. Monasta L, Ronfani L, Marchetti F, et al; Burden of disease caused by otitis media: systematic review and global estimates. PLoS One. 20127(4):e36226. Epub 2012 Apr 30.

  6. Qureishi A, Lee Y, Belfield K, Birchall JP, Daniel M. Update on otitis media – prevention and treatment. Infection and Drug Resistance. 2014;7:15-24. doi:10.2147/IDR.S39637.

  7. Olatoke F, Ologe FE, Nwawolo CC, et al; The prevalence of hearing loss among schoolchildren with chronic suppurative otitis media in Nigeria, and its effect on academic performance. Ear Nose Throat J. 2008 Dec87(12):E19.

  8. Gerami H, Naghavi E, Wahabi-Moghadam M, et al; Comparison of preoperative computerized tomography scan imaging of temporal bone with the intra-operative findings in patients undergoing mastoidectomy. Saudi Med J. 2009 Jan30(1):104-8.

  9. Basu S, Georgalas C, Sen P, et al; Water precautions and ear surgery: evidence and practice in the UK. J Laryngol Otol. 2007 Jan121(1):9-14. Epub 2006 Nov 14.

  10. Macfadyen CA, Acuin JM, Gamble C; Systemic antibiotics versus topical treatments for chronically discharging ears with underlying eardrum perforations. Cochrane Database Syst Rev. 2006 Jan 25(1):CD005608.

  11. Current Problems in Pharmacovigilance; Medicines and Healthcare products Regulatory Agency, December 1997

  12. Macfadyen CA, Acuin JM, Gamble C; Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations. Cochrane Database Syst Rev. 2005 Oct 19(4):CD004618.

  13. Sung L, Manji A, Beyene J, et al; Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials. Pediatr Infect Dis J. 2012 May31(5):431-5.

  14. Basavaraj S, Shanks M, Sivaji N, et al; Cochlear implantation and management of chronic suppurative otitis media: single stage procedure? Eur Arch Otorhinolaryngol. 2005 Oct262(10):852-5. Epub 2005 Mar 9.

  15. Hearing impairment - cochlear implants; NICE Technology Appraisal Guidance, January 2009

  16. Clinical commissioning policy; Bone anchored hearing aids, NHS Commissioning Board (2013)

  17. Yorgancilar E, Yildirim M, Gun R, et al; Complications of chronic suppurative otitis media: a retrospective review. Eur Arch Otorhinolaryngol. 2012 Jan 15.

  18. Kim J, Jung GH, Park SY, et al; Facial nerve paralysis due to chronic otitis media: prognosis in restoration of facial function after surgical intervention. Yonsei Med J. 2012 May53(3):642-8. doi: 10.3349/ymj.2012.53.3.642.

Ok, so I went to Greece with my cousin in July, and there both of us developed ear ringing at pretty much the same time. At first it was a hell, couldn't sleep, quite noticeable. Then we went to the...

Health Tools

Feeling unwell?

Assess your symptoms online with our free symptom checker.

Start symptom checker